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The activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) is an aggressive lymphoma
that is addicted to NF-kB signaling through the CARD11-BCL10-MALT1 complex. In this issue ofCancer Cell,
Nagel and colleagues and Fontan and colleagues describe MALT1 inhibitors suitable for clinical use that are
selectively toxic to this malignancy.Aberrant activation of NF-kB is a feature
shared by many human lymphomas due
to the ability of NF-kB to promote tumor
survival. In particular, constitutive NF-kB
activity is a hallmark of the ABC DLBCL
subtype. This DLBCL subtype is the
most recalcitrant to current immunoche-
motherapy regimens, due in part to
the anti-apoptotic properties of NF-kB
activity. Hence, targeted therapeutic
agents that shut down NF-kB in ABC
DLBCL are urgently needed.
ABC DLBCL tumors subvert normal
B cell signaling pathways to activate NF-
kB by acquiring somatic mutations that
activate and/or amplify their signaling
output (Figure 1). An RNA interference
screen identified a central role for
CARD11, BCL10, and MALT1 in the path-
ogenesis of ABC DLBCL cell lines (Ngo
et al., 2006). These three signaling effec-
tors form the ‘‘CBM’’ complex, which
serves as a signaling scaffold that recruits
TRAF6, TAK1, and the IKK complex to
activate the IkB kinase b (IKKb) and stim-
ulate NF-kB through the ‘‘classical’’
pathway. In 10% of ABC DLBCL cases,
somatic mutations affecting the coiled-
coil domain of CARD11 spontaneously
induce the formation of the CBM complex
and NF-kB activity (Lenz et al., 2008).
Other ABC DLBCL lymphomas lack
CARD11 mutations but, nevertheless,
rely upon wild-type CARD11 to activate
NF-kB and sustain survival (Ngo et al.,
2006). These ABC DLBCL tumors rely
upon a ‘‘chronic active’’ form of BCR
signaling to engage CARD11 and the
NF-kB pathway (Davis et al., 2010). ABC
DLBCLs with wild-type CARD11 die
upon knockdown or pharmacologic in-
hibition of any component of the BCR
signaling cascade (Davis et al., 2010).
Recurrent mutations in the BCR subunits706 Cancer Cell 22, December 11, 2012 ª20CD79B and CD79A occur in roughly one
fifth of ABC DLBCL cases, providing
genetic evidence that chronic active
BCR signaling is important in ABC DLBCL
pathogenesis (Davis et al., 2010).
BCR pathway inhibitors are currently
being investigated in clinical trials to eval-
uate their efficacy against ABC DLBCL
and other forms of B cell lymphoma.
These inhibitors chiefly target either BCR
proximal kinases, such as BTK and SYK,
or the phosphatidylinositol 3-kinase path-
way that emanates from theBCR. Promis-
ing responses have been observed,
including complete and partial responses
to the BTK inhibitor ibrutinib in ABC
DLBCL. However, experiments in cell
lines suggest that these upstream BCR
pathway inhibitors will be unable to treat
tumors that harbor oncogenic CARD11
mutations, necessitating alternative ther-
apies for these patients.
The recently described proteolytic
activity of MALT1 provides a new target
for therapeutic development (reviewed in
McAllister-Lucas et al., 2011). The cas-
pase-like domain of MALT1 cleaves sub-
strates following arginine residues, unlike
conventional caspase that cleave after
aspartate residues. MALT1 cleaves and
disables A20 (TNFAIP3) and CYLD, both
negative regulators of NF-kB, thereby
potentiating NF-kB signaling. Based on
these results in normal lymphocytes, two
groups demonstrated that MALT pro-
tease activity is required for NF-kBactivity
and survival of ABC DLBCL cells (Ferch
et al., 2009; Hailfinger et al., 2009). A
peptide inhibitor of MALT1 paracaspase
activity was toxic to ABC DLBCL cell
lines, but not to models of other lym-
phoma subtypes. In theory, MALT1
should make an excellent therapeutic
target. First, MALT1 knockout mice are12 Elsevier Inc.defective in T and B cell activation
but are otherwise healthy. Second, the
paracaspase domain of MALT1 is unique
within the human genome, suggesting
that a MALT1 inhibitor might not cause
significant off-target side effects.
In this issue of Cancer Cell, Nagel et al.
(2012) and Fontan et al. (2012) report the
discovery of small molecule inhibitors
of MALT1 that represent a new class of
lymphoma therapeutics. Both studies
utilized in vitro MALT1 protease assays
in high-throughput screens of small mole-
cule libraries, yielding inhibitors of MALT1
activity at low micromolar concentrations
in vitro. In a library of drugs approved for
human use, Nagel et al. (2012) identified
three phenothiazines, a class of anti-
psychotic drugs, which inhibit MALT1
paracaspase activity and kill ABC DLBCL
cells. The doses necessary to inhibit the
growth of ABC DLBCL xenografts were
equivalent to those achieved when hu-
mans are given these drugs, suggesting
that they could be used off-label in clinical
trials soon. While phenothizines may be
tolerated for short term chemotherapy,
their long-term use will be limited by the
already known side effects characteristic
of this drug class, for example tardive
dyskinesia. Fontan et al. (2012) discov-
ered a novel small molecule, termed
MI-2, that notably inhibited MALT1 by
forming a covalent linkage in the active
site. Although traditional drug develop-
ment has shied away from irreversible
inhibitors because of potential crossreac-
tivity and immunogenicity, they afford
outstanding pharmacodynamic proper-
ties. Indeed, the hepatitis C NS3/4A
protease inhibitor Telaprevir and the
proteasome inhibitor Carfilzomib are
both irreversible. Likewise, the unusual
potency of ibrutinib in many lymphoid
Figure 1. Role of MALT1 in Signaling to NF-kB in ABC DLBCL
Two prominent pathways leading to NF-kB activation in ABC DLBCL are shown: chronic active BCR
signaling and constitutiveMYD88 signaling. MALT1 plays a key role in the BCR pathway in twoways. First,
as a component of the CBM complex with CARD11 and BCL10, MALT1 helps recruit and activate IkB
kinase (IKK). Second, MALT1 protease activity potentiates NF-kB signaling by cleaving and inactivating
two negative regulators of IKK, A20 (TNFAIP3), and CYLD. Recurrent mutations in ABC DLBCL tumors
that cause or intensify NF-kB activity are shown.
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Previewsmalignancies may be due to its covalent
attachment to BTK. While MI-2 is a lead
compound that may require further opti-
mization, it is notable that mice treated
with MI-2 did not have detectable physio-
logical, histological, or biochemical signs
of toxicity.
Clinical trials with correlative studies
will be needed to determine the lym-
phoma phenotypes and genotypes that
are best suited to MALT1-directed
therapy. While the BCR pathway inhibitor
ibrutinib is showing promising activity in
clinical trials, it is too early to know what
mechanisms of resistance may develop.
From this perspective, we cannot really
have too many targeted therapies, espe-
cially ones that have few if any side
effects. An important niche not addressed
by the BCR pathway inhibitors would be
the 10% of ABC DLBCL tumors with
CARD11 mutations. MALT1 inhibitors
might also be potentially useful in some
cases of germinal center B cell-like(GCB) subtype of DLBCL, since CARD11
mutations occur inz5% of these tumors
and are associated with elevated NF-kB
activity compared to the majority of GCB
DLBCLs (Lenz et al., 2008). Gastric
MALT lymphomas with a t(11;18) translo-
cationmay be another venue because this
translocation creates a fusion oncopro-
tein composed of protein interaction
domains from c-IAP2 and the MALT1 par-
acaspase domain that is proteolytically
active (McAllister-Lucas et al., 2011).
Germline CARD11 coiled-coil domain
mutations have recently been identified
in families with a congenital B lymphocy-
tosis, which can progress to chronic
lymphocytic leukemia. MALT1 inhibitors
could prove useful in this setting if they
can be tolerated long-term without side
effects (Snow et al., 2012). Finally, it
should be noted that a second prominent
signaling pathway can activate NF-kB in
ABC DLBCL via the signaling adaptor
MYD88. Recurrent somatic mutations ofCancer Cell 22, DMYD88 occur in 39% of ABC DLBCLs,
with one particularly potent point mutant,
MYD88 L265P, occurring in 29% of cases
(Ngo et al., 2011). Some ABC DLBCLs
have both MYD88 L265P and CD79B
mutations (Ngo et al., 2011), and cell line
models of such cases rely on MALT1 for
survival (Fontan et al., 2012). However,
other ABC DLBCLs only have MYD88
mutations and are not dependent upon
BCR signaling (Ngo et al., 2011), and
these do not respond to MALT1 inhibition
(Fontan et al., 2012). Thus, the optimum
deployment of MALT1 inhibitors awaits
a precise definition of which ABC DLBCL
tumors rely upon BCR signaling through
MALT1 for survival.REFERENCES
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